Antimalarial Drugs In Pregnancy: Preclinical And Clinical Studies Of Conventional And Novel Agents
Funder
National Health and Medical Research Council
Funding Amount
$470,115.00
Summary
Women in malaria-endemic areas such as coastal PNG are at high risk of malaria in pregnancy. To prevent the substantially increased malaria-associated morbidity and mortality in mother and child, and because even asymptomatic infections can be deleterious, there has been a move to giving antimalarial drugs regularly during pregnancy regardless of the mother's clinical or parasitological status. In poor tropical countries, such treatment usually comprises safe and inexpensive agents such as chlor ....Women in malaria-endemic areas such as coastal PNG are at high risk of malaria in pregnancy. To prevent the substantially increased malaria-associated morbidity and mortality in mother and child, and because even asymptomatic infections can be deleterious, there has been a move to giving antimalarial drugs regularly during pregnancy regardless of the mother's clinical or parasitological status. In poor tropical countries, such treatment usually comprises safe and inexpensive agents such as chloroquine and Fansidar. There are two main issues with this approach. First, the efficacy of such conventional agents is waning and this increases the risk of break-through malaria. Second, there are few data on how the drugs are handled in pregnancy on which to base recommendations for treatment. We plan to collect information on the disposition and effectiveness of chloroquine and Fansidar in women with malaria in pregnancy in PNG that should allow a critical appraisal of the usefulness of current regimens in PNG and in other tropical countries where parasite resistance to these agents is emerging. Artemisinin combination therapy (ACT) in the form of a novel artemisinin drug and a longer-acting partner has been suggested as the most promising alternative therapy for malaria in pregnancy if conventional drugs fail. We plan to assess the safety of a leading ACT formulation, namely dihydroartemisinin and the chloroquine-like drug piperaquine (DHA-PQ), in animals before extending our studies to women with malaria in PNG. These latter studies will allow an evaluation of the safety and efficacy of DHA-PQ as novel therapy for malaria in pregnancy in PNG and other tropical countries.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE150100081
Funder
Australian Research Council
Funding Amount
$220,000.00
Summary
DomeLab: an ultra-high resolution experimental fulldome. DomeLab - an ultra-high resolution experimental fulldome: This project will establish the first ultra-high resolution (4000 x 4000 pixels) experimental fulldome in Australia (DomeLab). This fulldome facility will provide a powerful immersive dome-based video projection environment. Partners will work collaboratively across three themes: interactive media, future museology and experimental humanities. Through the national research services ....DomeLab: an ultra-high resolution experimental fulldome. DomeLab - an ultra-high resolution experimental fulldome: This project will establish the first ultra-high resolution (4000 x 4000 pixels) experimental fulldome in Australia (DomeLab). This fulldome facility will provide a powerful immersive dome-based video projection environment. Partners will work collaboratively across three themes: interactive media, future museology and experimental humanities. Through the national research services AARNet and Intersect's research data storage infrastructure, DomeLab will extend pioneering research in aesthetic frameworks and frontier technologies to benefit artistic, cultural, museological and humanities researchers. DomeLab is designed as a touring system and will be installed throughout the country at leading institutions. Read moreRead less
Unravelling The Mechanism Of MHC Class-I Associated Drug Hypersensitivities
Funder
National Health and Medical Research Council
Funding Amount
$566,308.00
Summary
Some drugs cause adverse reactions that are life threatening. We think these reactions are mediated by killer T cells as they are genetically controlled by immune response genes that normally guide immunity to microbes. We will study immune reactions to the drug abacavir, used to treat HIV (AIDS); allopurinol used to prevent gout and carbamazepine, used to treat epilepsy. The study may also help devise better treatments for patients who experience severe forms of these reactions.
A Phase III Trial Comparing Adjuvant Versus Salvage Radiotherapy For High Risk Patients Post Radical Prostatectomy
Funder
National Health and Medical Research Council
Funding Amount
$819,138.00
Summary
About half of all patients Treated with an operation to remove their prostate cancer have a high chance of the cancer coming back. Giving immediate radiotherapy to all patients will improve cure rates but does not benefit all men and can cause significant side effects. This study explores whether it is safe to wait and only give radiotherapy when there is a rising PSA after surgery indicating active cancer. A total of 470 men from Australasia will enter this study comparing the two approaches.
Discovery Early Career Researcher Award - Grant ID: DE130101712
Funder
Australian Research Council
Funding Amount
$369,706.00
Summary
Disability and digital TV: access, representation and reception. Digital television has the potential to lesson the social exclusion of people with disability, if it is made accessible. This project will provide a much-needed user-focused analysis of two areas of key concern to Australians with disability as the nation switches over to digital TV - access and representation.
Young People, Technology, and Wellbeing Research Facility. Large numbers of initiatives now mobilise technology to support the wellbeing of young Australians. However, amongst communities undertaking this work, there is currently significant duplication and insufficient sharing of research and best practice models. A Research Facility that consolidates existing research, and guides new research and initiatives will improve service delivery to young Australians by: reducing duplication between or ....Young People, Technology, and Wellbeing Research Facility. Large numbers of initiatives now mobilise technology to support the wellbeing of young Australians. However, amongst communities undertaking this work, there is currently significant duplication and insufficient sharing of research and best practice models. A Research Facility that consolidates existing research, and guides new research and initiatives will improve service delivery to young Australians by: reducing duplication between organizations working with young people; providing an accessible interface with research that can help address the community’s concerns about the role of technology in young people’s lives, and inform future policy and programs; and model effective cross-sector knowledge brokering to Australian industry. Read moreRead less